6.2 C
London
Tuesday, December 24, 2024
Subscribe
Home Tags SinoMab

Tag: SinoMab

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
Business

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy

-
0
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
Business

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

Editor -
0
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
Business

SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE

Editor -
0
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
Business

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

-
0
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
Business

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

-
0
SinoMab Received the Highest Subsidy from HKSTP
Business

SinoMab Received the Highest Subsidy from HKSTP

-
0
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.
Business

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

-
0
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Business

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

-
0
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Business

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

-
0
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Business

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

-
0
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Uncategorized

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

-
0
© Newspaper WordPress Theme by TagDiv